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Global funding trends for malaria research in sub-Saharan 
Africa: a systematic analysis
Michael G Head, Sian Goss, Yann Gelister, Victor Alegana, Rebecca J Brown, Stuart C Clarke, Joseph R A Fitchett, Rifat Atun, J Anthony G Scott, 
Marie-Louise Newell, Sabu S Padmadas, Andrew J Tatem
Summary
Background Total domestic and international funding for malaria is inadequate to achieve WHO global targets in burden 
reduction by 2030. We describe the trends of investments in malaria-related research in sub-Saharan Africa and compare 
investment with national disease burden to identify areas of funding strength and potentially neglected populations. We 
also considered funding for malaria control.
Methods Research funding data related to malaria for 1997–2013 were sourced from existing datasets, from 13 major 
public and philanthropic global health funders, and from funding databases. Investments (reported in US$) were 
considered by geographical area and compared with data on parasite prevalence and populations at risk in sub-
Saharan Africa. 45 sub-Saharan African countries were ranked by amount of research funding received.
Findings We found 333 research awards totalling US$814·4 million. Public health research covered $308·1 million 
(37·8%) and clinical trials covered $275·2 million (33·8%). Tanzania ($107·8 million [13·2%]), Uganda ($97·9 million 
[12·0%]), and Kenya ($92·9 million [11·4%]) received the highest sum of research investment and the most research 
awards. Malawi, Tanzania, and Uganda remained highly ranked after adjusting for national gross domestic product. 
Countries with a reasonably high malaria burden that received little research investment or funding for malaria 
control included Central African Republic (ranked 40th) and Sierra Leone (ranked 35th). Congo (Brazzaville) and 
Guinea had reasonably high malaria mortality, yet Congo (Brazzaville) ranked 38th and Guinea ranked 25th, thus 
receiving little investment.
Interpretation Some countries receive reasonably large investments in malaria-related research (Tanzania, Kenya, 
Uganda), whereas others receive little or no investments (Sierra Leone, Central African Republic). Research 
investments are typically highest in countries where funding for malaria control is also high. Investment strategies 
should consider more equitable research and operational investments across countries to include currently neglected 
and susceptible populations.
Funding Royal Society of Tropical Medicine and Hygiene and Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
The current total domestic and international investments 
in malaria are considered grossly inadequate to meet the 
annual global target for investment of US$6 billion.1 The 
2015 Global Burden of Disease study estimated that there 
were 731 000 malaria-associated deaths (a decline of 
about 37% since 2005, along with a decline in age-
standardised mortality of 43%)2 and 296 million positive 
cases (a decline of about 30% since 2005) in 2015,3 with a 
high prevalence in sub-Saharan Africa.4 To address this 
burden, malaria is the focus of large and well funded 
programmes from influential global health actors such as 
The Global Fund5 and the Bill & Melinda Gates Foundation, 
both of which have targeted malaria for elimination.6
An estimated US$8·9 billion was disbursed globally 
for malaria control and elimination programmes 
between 2006 and 2010, with most of this funding 
targeted to Africa.7 As well as provision of finance from 
The Global Fund, substantial investment came from 
other actors, such as the World Bank and the President’s 
Malaria Initiative. As investment specifically focused on 
malaria control increases, the burden of malaria 
decreases,8 with interventions estimated to have averted 
663 million clinical cases of malaria globally since 2000. 
Insecticide-treated nets, the most widespread 
intervention, were responsible for 68% of the averted 
cases.9 However, a substantial burden still remains, 
requiring efficient allocation of scarce financial resources 
to address gaps in implementation and research.
The ten largest global health research funders, which 
include the US National Institutes of Health, the European 
Commission, the Wellcome Trust, and the Bill & Melinda 
Gates Foundation, collectively invest about $37·1 billion 
into research each year,10 and malaria is a research priority 
or part of a wider focus (eg, global health) for these 
organisations. Investments cover the full pipeline of 
research, from preclinical science, to clinical trial phases 
and product development, and on to implementation and 
operational research. However, few multi-funder analyses 
of the focus of these awards exist.
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The Research Investments in Global Health study 
(ResIn) has analysed funding trends in infectious disease 
research awarded to UK institutions11,12 and has identified 
Africa as being the focus of much of the UK global health 
research portfolio.13 Here, we aimed to systematically 
analyse investments in research related to malaria from 
leading international donors, in particular when the 
focus of the project was in sub-Saharan Africa. We also 
aimed to locate the site of the research at the national 
level, describe the geography of investment trends, and 
compare investments with the local prevalence of malaria 
caused by Plasmodium falciparum and malaria burden, as 
measured by the sizes of at-risk populations.
Methods
Search strategy and selection criteria
The process of collating and categorising infection-
related research awards to UK institutions for this 
systematic analysis has been described in detail 
elsewhere.11–13 Briefly, we extracted award data for studies 
of infectious diseases from funder’s websites or 
requested award data directly from the funder. We also 
searched funding databases, such as the National 
Research Register, owned by the UK Department of 
Health, and clinicaltrials.gov, for infection-related 
awards. Each award was individually scrutinised and 
categorised under a number of diseases, disease areas 
(eg, global health, antimicrobial resistance), and by type 
of science (eg, phase 1–3 clinical trials, public health 
research). Award types included project grants, 
programme grants, fellowships, and pump-priming 
(development grants) or pilot projects that had a clear 
research component to the project.
We focused specifically on awards relating to malaria 
research in sub-Saharan Africa. We used the UK portfolio 
already collated by the ResIn study12 and further 
considered 28 leading funders of global health research 
(see appendix 1 for the full list of funders that were 
assessed, including those that did not have data that met 
the inclusion criteria). We used existing knowledge and 
data from the ResIn study, author knowledge, and 
healthresearchfunders.org to identify key funders who 
were likely to have provided research investment for 
malaria. Much of the newly collected data were sourced 
from the Dimensions for Funders database, 
UberResearch. When searching online databases for 
awards related to malaria, we used the search terms 
“malaria”, “plasmodium”, and “anopheles”. From the 
retrieved awards, we reviewed the title and abstract to 
ascertain whether the project had a focus in the 45 sub-
Saharan African nations for which data were available. 
When information about the project was insufficient, we 
searched databases (including the UK Research Councils‘ 
Gateway to Research database, PubMed, and Europe 
PMC) for publications related to the original award and 
for information about the award on institutional or study-
specific websites. We included awards for which the 
commitment to fund was dated between 1997 and 2013 
(inclusive). The UK Department for International 
Development and the Bill & Melinda Gates Foundation 
fund both research and implementation activity; here, we 
only included the research projects. Using the malaria 
awards from the preexisting ResIn UK dataset as an 
example, we included awards of greater than $150 000 
(the 10th percentile in the UK dataset). Awards solely 
related to preclinical science were excluded because they 
were unlikely to have a specific geographical focus; all 
other types of science along the research pipeline (from 
phase 1 studies through to public health and 
implementation research) were included.
Research in context
Evidence before this study
In July and August, 2016, we searched PubMed and the grey 
literature (via internet search engines and stakeholder 
websites, such as WHO) using the search terms “research 
investments”, “research funding”, “malaria investments”, 
“malaria funding”, and “malaria Africa” for articles written only 
in English. One author (MGH) also searched a personal 
Mendeley literature database that is built for the purpose of 
informing the Research Investments in Global Health (ResIn) 
study. Previous investment analyses include the study by 
Pigott and colleagues, ResIn publications, and the Policy Cures 
annual reports on product development research in infectious 
diseases.
Added value of this study
To the best of our knowledge, this is the first study to 
systematically describe the geography of public and 
philanthropic research funding for malaria in sub-Saharan 
Africa. The study combined and then re-analysed open data 
sources from numerous key global health investors, 
and categorised the awards via the classification system 
developed by the ResIn study. This strategy allowed us to 
provide a comprehensive overview of the investment 
landscape, with actionable data that can help inform equitable 
decisions around resource allocation.
Implications of all the available evidence
The findings show that much of the available resources are 
directed towards key global health hubs in sub-Saharan Africa—
for example, Tanzania, Uganda, and Kenya. However, several 
countries, such as Chad and Central African Republic, receive 
little or no research and operational funding despite having 
high malaria-associated burdens and mortality. These countries 
have neglected populations, and the global health community 
should reconsider strategies around resource allocation to 
reduce inequality and improve equity.
See Online for appendix
For more on UberResearch see 
http://www.uberresearch.com/
dimensions-for-funders
Articles
www.thelancet.com/lancetgh   Vol 5   August 2017 e774
Data analysis
We categorised the included awards as phase 1–3 trials, 
intervention and product development (including 
pharmacovigilance), public health research, or cross-
disciplinary research. Public health research included 
epidemiology, statistics and modelling, and implement-
ation and operational research. Cross-disciplinary 
research was defined as an award that clearly 
encompassed two types of science categories (ie, an 
award covering a phase 3 trial and pharmacovigilance 
research would be classified as cross-disciplinary). 
Awards were also categorised by tool or product, 
specifically diagnostics, vaccines, and therapeutics. 
Inter-author checks on categorisation yielded a fixed-
marginal κ score of 0·88 (indicating a reasonably high 
level of agreement between authors). All awards were 
adjusted for 2013 inflation and, when required, were 
converted to US$ by use of the average exchange rate in 
the year of the award. South Sudan and north Sudan 
were unified as Sudan for most of the time period 
under consideration and were therefore counted 
together (no investments were specifically for South 
Sudan after their separation).
Some included awards focused on malaria in multiple 
sites in multiple countries. Because it was not possible to 
establish the exact proportion of each award that was 
invested in or for each site, we used a pragmatic approach 
to divide the total award size evenly by the number of 
sites of focus as an approximate measure of likely 
allocation of resources. For example, for an award of 
US$1·5 million for malaria research in two sites in 
Kenya and one site in Tanzania, $1 million would be 
allocated to Kenya and $500 000 to Tanzania. Similarly, 
when an award had a clear focus on both malaria and 
other disease(s), for simplicity of analysis, the total 
investment was divided by the number of diseases 
involved. For example, a $1 million award for malaria 
and tuberculosis in Kenya would have resulted in 
$500 000 being allocated to malaria research, and the 
$500 000 assumed to be for tuberculosis research would 
have been excluded. Awards were not split when the 
focus was explicitly consideration of malaria as a 
coinfection with other diseases (the assumption being 
that all of the funding was for malaria-related burdens).
National-level disbursements of funding for malaria 
control for 2006–11 were included. Data up to 2010 have 
been published previously,7 and an author (MGH) 
provided one further year (2011) of unpublished 
disaggregated information about funding for malaria 
control (appendix 2). Donors included were national 
governments, UNICEF, the Global Fund, President’s 
Malaria Initiative, the World Bank, and the Development 
Assistance Committee. Levels of investment in funding 
for malaria control and research datasets were compared 
and ranked at the national level. World Bank data were 
used to compare 2013 national gross domestic product 
(GDP).14
Data for local prevalence of malaria caused by 
P falciparum were sourced from the Malaria Atlas 
Project,15 which had mapped variables including parasite 
prevalence and incidence of malaria between 2000 
and 2015. We used age-standardised, gridded P falciparum 
parasite prevalence data for ages 2–10 years (PfPR2–10) at 
5 km × 5 km spatial resolution. PfPR2–10 data were available 
for all included sub-Saharan African countries, with the 
exceptions of São Tomé and Príncipe and Comoros. The 
gridded PfPR2–10 data were summarised at the country 
level through integration with WorldPop gridded 
population data15 to construct population-weighted PfPR 
values for each country. All funding data for each country 
were combined, and maps were produced at the country 
level to display the total research investment per country 
between 1997 and 2013.
Role of the funding source
The funders had no role in the study design, data 
interpretation, or writing of the report. MGH had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
By research investment, 333 awards met the inclusion 
criteria, with a total inflation-adjusted amount for 
research funding of US$814·4 million (table 1). The 
mean award size was $2 445 591 (SD 4 054 664) and the 
median award size was $941 808 (IQR 419 529–$2 605 340). 
These findings show significant skew in the data, with a 
small number of very large awards driving the mean 
higher than the median. The total annual investment for 
malaria in sub-Saharan Africa varied substantially in the 
period of 1997–2015, although with a broadly increasing 
temporal trend alongside observed decreases in disease 
burden (figure 1). 317 (95%) research awards solely 
focused on malaria and 16 (5%) awards considered 
malaria alongside other infections. A total of 285 (86%) 
awards had just one country of focus.
By country, Tanzania, Uganda, Kenya, Malawi, and 
Ghana were the top five nations to receive the greatest 
amount of research investment, and 18 nations received 
greater than US$10 million of research funding (figure 2, 
figure 3, and table 2). Eight countries were not allocated 
research investments: Botswana, Cape Verde, Central 
African Republic, Chad, Congo (Brazzaville), Djibouti, 
Mauritania, and Sierra Leone.
By funder, the US National Institutes of Health 
provided the greatest investment of $292·0 million 
(36·4%), followed by the Bill & Melinda Gates Foundation, 
with a total investment of $144·1 million (17·9%); these 
two funders provided more than 40% of the research 
investments in all of the top five countries. Some nations 
were mostly reliant on investment from one funder—for 
example, the European & Developing Countries Clinical 
Trials Partnership provided 79% ($10·2 million) of the 
research investment and was the main funder in Gabon.
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By type of science (table 1), investment for phase 1–3 
clinical trials totalled $275·2 million (33·8%) across 
80 (24%) awards. Public health investments totalled 
$308·1 million (37·8%) across 153 (46%) awards. Cross-
disciplinary research covered 65 (20%) awards and 
product development covered 35 (11%) awards. By 
product area, 83 (25%) awards were related to research in 
antimalarial therapeutics, with a total investment of 
$261·2 million (32·1%). 18 (5%) awards were related to 
vaccine research ($65·0 million [8·0%]), and 29 (9%) 
awards focused on diagnostic development ($41·0 million 
[5·0%]). There was no obvious association between the 
national population-weighted PfPR and the total research 
investment or funding for malaria control, by country 
(figure 4; appendix 1). Investments were distributed 
across high-burden, medium-burden, and elimination 
settings.
$8·1 billion of funding for malaria control was disbursed 
in the period of 2006–11 to 45 sub-Saharan African 
countries (table 2, appendix), with the lowest annual 
funding in 2006 ($585·2 million, 7·2%) and the highest 
annual funding in 2010 ($1·9 billion, 23·2%, appendix 2). 
The top five countries to receive funding in that period 
were Nigeria ($786·2 million, 9th in malaria research 
rankings), Tanzania ($750·0 million, ranked 1st in the 
research rankings), Kenya ($621·9 million, also ranked 
3rd in the research rankings), Ethiopia ($578·0 million, 
ranked 17th in the research rankings), and Malawi 
($424·6 million, ranked 4th in the research rankings; 
table 2). Ghana ranked in the top ten for both level of 
funding for malaria control (8th) and research 
investments (5th). Of the eight nations with no allocated 
research investment, all were ranked in the lowest third 
(30th or lower out of 45 countries) when considering 
funding for malaria control, with the exception of 
Sierra Leone (ranked 29th). The Gambia ranked 30th for 
funding for malaria control, but 8th for research 
investments. Most nations ranked similarly for both 
research investments and funding for malaria control.
Combined rankings showed the top five nations to be 
Tanzania, Kenya, Uganda, Malawi, and Nigeria. When 
adjusting for GDP (appendix), the top five nations to 
rank in the top ten across both funding for malaria 
control and research investment were Malawi, Tanzania, 
Uganda, Kenya, and Madagascar.
Discussion
Many research investments for malaria were focused in 
sub-Saharan Africa. We found that the greatest investments 
were allocated to Tanzania, Uganda, and Kenya. Malawi, 
Ghana, and Nigeria also ranked highly across both research 
investment and funding for malaria control. Investments 
for research were typically highest in countries where 
funding for malaria control was also high (The Gambia 
Number 
of awards
Proportion 
of total 
awards (%)
Total 
investment 
(US$)
Proportion 
of total 
investment (%)
Mean award size (US$)* Median award size (US$)†
Product area
Diagnostics 29 9% 41 010 386 5·0% 14 14 151 (1 670 125) 906 950 (409 574–1 430 935)
Vaccines 18 5% 64 995 864 8·0% 3 610 881 (3 394 021) 2 909 619 (510 504–4 855 510)
Therapeutics 83 25% 261 205 837 32·1% 3 147 058 (5 731 588) 991 048 (326 333–3 910 552)
Type of science
Phase 1–3 clinical trials 80 24% 275 214 430 33·8% 3 440 180 (4 787 761) 1 317 954 (426 077–4 955 076)
Intervention and 
product development 35 11% 87 580 346 10·8% 2 502 296 (4 186 004) 999 485 (293 800–2 605 340)
Public health 153 46% 308 076 978 37·8% 2 013 575 (4 053 184) 666 164 (375 387–2 209 865)
Cross-disciplinary 65 20% 143 510 172 17·6% 2 207 849 (2 630 770) 1 071 300 (552 164–2 517 231)
Total 333 NA 814 381 928 NA 2 445 591 (4 054 664) 941 808 (419 529–2 605 340)
NA=not applicable. *Data are mean (SD). †Data are median (IQR).
Table 1: Funding for malaria research in sub-Saharan Africa for 1997–2013 by product area and type of science
Figure 1: Sum of annual research investment for malaria in sub-Saharan Africa (1997–2013) and mean 
national-level PfPR for all countries in sub-Saharan Africa (2000–15)
PfPR=Plasmodium falciparum parasite prevalence.
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and Nigeria being notable exceptions). Similarly, most 
nations receiving little or no research investment for 
malaria also received scarce funding for malaria control, 
despite typically having a reasonably high malaria-related 
burden of disease. About a third of research investments 
were related to antimalarial therapeutics. The US National 
Institutes of Health and the Bill & Melinda Gates 
Foundation provided about 60% of research funding for 
malaria in sub-Saharan Africa, and funding was disbursed 
to countries with high and low burdens of malarial disease, 
indicating that drivers for allocation of investments are 
likely to include the desire to both reduce existing high 
burdens and to pursue efforts towards elimination in 
relatively low-burden settings. There appeared to be 
inequalities in overall disbursement of funding for malaria 
research, which will probably help to accelerate elimination 
in some settings but might neglect other vulnerable 
populations in locations of high malarial burden. 
Investments in malaria control broadly reflected the trends 
in research investment.
Evidence that investments in malaria research 
contribute to improved health outcomes is scarce, in part 
because of the numerous and complex variables that 
must be considered when assessing resource allocation. 
Thus, the correlation between increased research 
investment and decreased burden cannot in itself be 
considered causal. Funding for malaria control also 
increased between 2006 and 2011, and interventions, 
including bednets and therapeutics, have clearly had 
substantial impacts.9 Case studies provide qualitative 
evidence to justify investments in global health research,16 
and the findings presented here lend some weight to that 
conclusion. To qualify and address the gaps in evidence, 
WHO has established the Global Observatory on Health 
Research and Development,17 and is openly seeking 
evidence-based contributions to assimilate existing 
knowledge and inform global strategies.18 The ResIn 
study is also scheduled to report findings of a global 
research investments analysis for all infectious diseases 
in 2017.
Investing requires confidence on the part of the investor 
that they will see a return on their investment (for example, 
health gains from operational investments such as 
provision of insecticide-treated nets, or research 
investments that generate new knowledge or products 
such as vaccines and diagnostics). Therefore, particularly 
in environments where the logistics for research might be 
complex and challenging, the inclination is to fund 
Figure 2: Total research investment (US$ millions) for malaria sourced per country for 1997–2013
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0
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>30
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governments and institutions with a track record of 
success and in locations where it is perceived that the 
investment will make a positive difference and where any 
research will be feasible. Thus, countries such as Tanzania, 
Uganda, and Kenya, which all have existing relatively good 
infrastructures for research (such as the Kenya Medical 
Research Institute sites in Nairobi and Kilifi), continue to 
receive steady sums of research investment and also 
benefit from relatively high levels of funding for malaria 
control. From these streams of funding, high-quality 
research that provides clarity on the research questions 
under investigation is likely. Conversely, funders do not 
have the incentive or confidence to invest in African 
nations such as Chad, Somalia, and the Central African 
Republic, which are considered politically fragile and have 
inadequate infrastructure and regulations surrounding 
business start-ups and trading.19 The USA and the UK are 
leading investors in global health and, specifically, in 
provision of funding for malaria, but the changeable 
political climates in both countries might have implications 
for global health investment and activity.
Other factors that influence resource allocation include 
political and socioeconomic factors such as conflict, 
corruption, and crime and economic considerations. 
Poorer nations with weak infrastructures are less likely to 
reap the benefits from research investment without 
improvements in health systems. For example, eight of 
the top ten nations considered most susceptible to 
infectious disease outbreaks are in sub-Saharan Africa, 
and the three most susceptible are Somalia (ranking 34th 
in our investment rankings), Central African Republic 
(ranking 40th in our investment rankings), and Chad 
(ranking 36th in our investment rankings).20 Corruption 
indices rank Somalia as the worst performer, with 
numerous sub-Saharan African nations ranked in the 
lower percentiles.21 In a systematic analysis22 of the 
geographical distribution of global health partnerships 
with the 100 highest-ranked universities worldwide, 
Kenya, Tanzania, and Uganda had 43 partnerships. Of 
the 12 countries that ranked lowest in our investment 
rankings, only Sierra Leone, with five partnerships, and 
Botswana, with three partnerships, had any recorded 
global health partnerships.22 The global health 
partnership analysis22 also described areas in northern 
and central Africa that had either few or no partnerships 
with high-ranking universities, despite these areas being 
Figure 3: Sum funding for malaria research in sub-Saharan Africa, by country and funder, for 1997–2013
Other included French National Research Agency, National Science Foundation, Research Council of Norway, Swedish Research Council, Swiss National Science 
Foundation, US Food and Drug Administration, and Economics and Social Research Council. EDCTP=The European & Developing Countries Clinical Trials Partnership. 
DRC=Democratic Republic of the Congo.
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Research investment for malaria Funding for malaria control Combined rankings
Award 
numbers
Investment 
allocated (US$)
Ranking Total funds (US$) Ranking Difference between 
funding and 
research rankings
Sum of funding 
and research 
rankings
Overall 
ranking*
Tanzania 170 107 769 388 1 749 985 362 2 1 3 1
Kenya 148 92 938 771 3 621 884 255 3 0 6 2
Uganda 115 97 865 177 2 390 362 646 6 4 8 3
Malawi 67 71 664 330 4 424 565 187 5 1 9 4
Nigeria 36 32 639 664 9 786 174 145 1 –8 10 5
Ghana 83 62 725 691 5 345 841 459 8 3 13 6
Mozambique 19 16 358 722 13 350 860 934 7 –6 20 7
Ethiopia 28 12 557 685 17 577 983 173 4 –13 21 8
Zambia 34 27 775 658 10 253 054 196 14 4 24 9=
Madagascar 22 15 944 015 14 309 559 262 10 –4 24 9=
Mali 42 45 135 562 7 175 217 824 18 11 25 11
Senegal 36 27 509 977 11 218 009 244 15 4 26 12
Democratic 
Republic of 
the Congo
13 10 930 149 18 331 377 636 9 –9 27 13
Benin 20 17 095 744 12 203 545 688 16 4 28 14=
South Africa 8 14 896 558 15 275 467 512 13 –2 28 14=
Burkina Faso 70 47 333 448 6 106 721 492 23 17 29 16
Rwanda 12 2 933 323 24 299 031 287 12 –12 36 17
The Gambia 61 38 653 641 8 41 275 673 30 22 38 18
Cote d’Ivoire 11 9 535 162 19 129 028 300 20 1 39 19
Togo 4 2 965 449 23 163 947 976 19 –4 42 20
Zimbabwe 6 7 726 559 21 114 130 493 22 1 43 21
Cameroon 15 9 133 108 20 99 854 472 24 4 44 22
Sudan 7 1 749 370 28 178 508 093 17 –11 45 23
Angola 1 117 993 36 300 977 800 11 –25 47 24
Guinea 4 3 224 682 22 44 039 001 28 6 50 25
Gabon 13 12 886 319 16 21 071 247 36 20 52 26
Niger 7 2 122 215 26 64 687 908 27 1 53 27
Liberia 1 297 205 33 121 097 057 21 –12 54 28
Burundi 3 982 238 31 67 946 385 26 –5 57 29
Namibia 4 292 409 34 74 777 578 25 –9 59 30
Equatorial 
Guinea
4 1 908 866 27 34 065 864 33 6 60 31=
Eritrea 2 1 662 342 29 39 739 873 31 2 60 31=
Guinea-Bissau 5 2 772 862 25 15 118 865 38 13 63 33
Somalia 2 604 537 32 26 459 527 34 2 66 34
Sierra Leone 0 0 38 42 116 404 29 –9 67 35
Swaziland 2 1 049 598 30 12 763 749 40 10 70 36=
Chad 0 0 38 37 921 952 32 –6 70 36=
Congo 
(Brazzaville)
0 0 38 23 751 153 35 –3 73 38
Mauritania 0 0 38 15 373 467 37 –1 75 39
Comoros 1 224 619 35 7 254 263 42 7 77 40=
Central African 
Republic
0 0 38 13 812 987 39 1 77 40=
São Tomé and 
Príncipe
1 27 804 37 7 929 237 41 4 78 42
(Table 2 continues on next page)
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in great need of health care and thus surely also in 
particular need of investment (institutions ranked 
outside of the top 100 will potentially have international 
partnerships that were undocumented in the global 
health partnership analysis and might include the lower-
ranked nations here). Capacity building and training 
initiatives, and geographical priorities set by research 
funders, might help incentivise leading academic 
institutions to develop new partnerships with sub-
Saharan African countries. Our findings correspond with 
other analyses23 in showing broadly low sum investments 
in central Africa, with resources mostly concentrated in 
western and eastern Africa. High malaria mortality and 
low coverage (<50%) of insecticide-treated bednets are 
seen in lower-ranked countries in these central regions, 
such as Congo (Brazzaville), Guinea, and Central African 
Republic.14 The five countries ranked lowest in terms of 
their likelihood to meet the targets set in the health-
related UN Sustainable Development Goals were Central 
African Republic, Somalia, South Sudan, Niger, and 
Chad.24 There are huge differences in the amount of 
investment each high-income nation will allocate to 
global health operational and research investments and 
so, when the amount of resource allocated to each low-
income or middle-income nation is linked to the 
wealthier nation’s historical ties,13 there is the potential 
for inequalities in resource allocation to be introduced 
and for health issues to be inadequately addressed.
Research investment for malaria Funding for malaria control Combined rankings
Award 
numbers
Investment 
allocated (US$)
Ranking Total funds (US$) Ranking Difference between 
funding and 
research rankings
Sum of funding 
and research 
rankings
Overall 
ranking*
(Continued from previous page)
Djibouti 0 0 38 6 763 868 43 5 81 43
Botswana 0 0 38 5 870 021 44 6 82 44
Cape Verde 0 0 38 2 029 301 45 7 83 45
Countries are ordered by their overall ranking. *Overall ranking is the sum ranking in order.
Table 2: Total funding and rankings for malaria research and control investments by country
Figure 4: Comparison of 2015 population-weighed parasite prevalence and total research investment received for 1997–2013 by sub-Saharan African nation
DRC=Democratic Republic of the Congo.
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Research outputs can translate across national borders, 
but might not do so without appropriate consideration of 
the context in which research findings are used. 
Substantial advantages exist in investment in local 
research, particularly with regards to ownership of the 
results, trust, inter-sector sharing of expertise between 
researchers and policy makers, and increased 
contextualisation of findings.25 If little or no local track 
record in research exists, then inter-sector expertise 
might be less likely.26 Decision-makers will assess 
research findings by taking into account the political 
context,27 the capacity of local health systems to absorb 
the knowledge and put the innovation into practice, and 
the appropriateness of the proposed intervention.28 
The Lancet’s Commission on Global Health 203529 
highlighted how low-income nations such as Chad or 
Somalia could experience substantial health gains with 
an “enhanced R&D investment scenario” deployed at a 
national level, alongside societal benefits. Investment in 
biomedical science research and development in the UK 
yields a 17% return to the economy, and each pound of 
public investment stimulates the same investment from 
the private sector.30 New investment in research and 
development in low-income settings could potentially be 
the catalyst for improved health systems and confidence 
in the business and academic sectors.
In 2015, WHO announced a new global strategy for 
addressing malaria between 2016 and 2030, for which the 
target is to reduce the global malaria burden by 90% 
before 2030.4 Innovation and research is one of the three 
major pillars of that strategy. WHO estimates that 
additional funding of $673 million annually is needed for 
malaria research,4 a substantial increase compared with 
current funding, and that $6·4 billion is needed every 
year for funding of malaria control.1 Research 
recommendations include analysis of transmission-
blocking medicines in high-transmission settings, 
investigation of the short-term and long-term effects of 
administration of effective antimalarials, implementation 
research that refines approaches to application of existing 
interventions to make them more effective and more 
efficient in local contexts, diagnostics that detect low-
level parasitaemia in asymptomatic carriers, and research 
to develop more effective vaccines. The African Union 
health strategy for years 2016–30 aims to “increase 
investments in health, improve equity and address social 
determinants of health”.31 One of the strategic areas is to 
“end malaria”,31 although little specific detail is available 
on how this could be achieved. Further tracking of 
resource allocation, such as with research portfolios, is 
essential to inform strategies that will allow WHO’s 
ambitious 90% reduction target to be met.
Limitations of the ResIn analyses have been previously 
described in full.11,12 The research funding data included 
here were sourced from probably the largest public and 
philanthropic contributors to global health and malaria-
related research; however, resource constraints pre vented 
inclusion and analysis of other national funders who 
might provide further investment in their countries of 
focus. We also excluded preclinical science and malaria 
research focused on nations outside of sub-Saharan Africa, 
although findings from such studies might eventually 
inform sub-Saharan-African-focused strategies. The 
Global Fund and President’s Malaria Initiative typically do 
not consider their investments as research but as 
operational activity; thus, they were not included in the 
research analyses but were included in the funding for 
malaria control dataset.7 The Bill & Melinda Gates 
Foundation provides investments for both research and 
operational activity; however, scarce information was 
openly available on the Foundation’s grants database, and 
categorisation of these awards was therefore sometimes 
difficult. Private sector investments were not available for 
detailed systematic analyses and thus were not included, 
leading to a clear data gap, particularly in investment 
directed towards research for new products. However, 
almost all financing for malaria vaccine research and drug 
development comes from public and philanthropic 
sources.32 Some of the research investments not included 
here in the public, philanthropic, or private sectors might 
have been focused on countries that we found to be 
neglected in terms of receipt of investment in our analysis. 
Although we found correlations between temporal levels 
of investment and disease burden, causality could not be 
inferred from those results. The categorisation process 
was subjective and we made assumptions about allocations 
of awards, athough we took care to reduce subjectivity; the 
high κ score on inter-observer concordance indicates a 
high level of agreement between authors and inter-author 
checks reduced the likelihood of systematic error.
To the best of our knowledge, this is the first study to 
systematically analyse both research and operational 
investments for malaria in sub-Saharan Africa. 
Reasonable consistency in amounts of FMC and research 
investment was seen in those African nations that benefit 
from receipt of significant shares of available resources 
and consistent inequalities were seen in those that do 
not; many countries receiving little in the way of 
investment are those with the highest burden of malaria 
and the weakest health systems and infra structures. 
Evidence suggests that ownership of research findings 
increases their uptake and that, although doing research 
in some settings is extremely challenging because of 
negative political and socio economic factors, these areas 
contain some of the world’s most vulnerable populations. 
Thus, careful investment strategies should consider how 
these populations can best be reached.
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